FDA issues letter of support for
urinary peptide-based biomarker
to detect early stage of CKD.
-
Mosaiques featured in Horizon Magazin
-
Mosaiques nominated for Innovationspreis Niedersachsen 2018
-
fünfzehN Jahre NBank & mosaiques Group
-
Clinical Proteomics on the Path Toward Implementation: First Promises Delivered
-
Urinary peptide panel for prognostic assessment of bladder cancer relapse.
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure.
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment.
Copyright © 2019,
Design by Zymphonies